Kv7 channel activators -a novel treatment for preterm labour?

Kv7 通道激活剂 - 一种治疗早产的新方法？

• 批准号: G1100243/1
• 负责人: Rachel Tribe
• 金额: $ 95.4万
• 依托单位: King's College London
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2012
• 资助国家: 英国
• 起止时间: 2012 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=G1100243%2F1
• 关键词: Kv7; channel; activators; novel; treatment

Every year, over 40,000 babies are born too early. Whilst some of these babies will be healthy, many will die shortly after birth and those who survive risk developing lifelong disability or behavioural problems. Ideally, obstetricians would like to be able to predict which women are at risk of delivering their baby prematurely and prevent them going into labour too early. However, this is not yet possible and women present at hospital in preterm labour requiring drugs to stop their uterus (womb) from contracting. The drugs currently available are not very effective and there is a real need to develop better treatments. Our research has identified a new class of drugs (Kv7 channel activators) that can potentially stop the uterus from contracting. Before we can begin testing these drugs in pregnant women, we need to show that they are safe to use in pregnancy. Our project aims to do this and also to develop our understanding of how these drugs can target the uterus specifically.

每年有4万多婴儿早产。虽然这些婴儿中有一些是健康的，但许多婴儿在出生后不久就会死亡，而那些幸存下来的婴儿可能会终身残疾或出现行为问题。理想情况下，产科医生希望能够预测哪些妇女有早产的风险，并防止她们过早分娩。然而，这还不可能，在医院早产的妇女需要药物来阻止她们的子宫收缩。目前可用的药物不是很有效，真实的需要开发更好的治疗方法。我们的研究已经确定了一类新的药物（Kv7通道激活剂），可以潜在地阻止子宫收缩。在我们开始在孕妇中测试这些药物之前，我们需要证明它们在怀孕期间使用是安全的。我们的项目旨在做到这一点，并发展我们对这些药物如何特异性靶向子宫的理解。